GlassScriptPhysician profile
Akhil B Patel
NPI 1457617714
$7,074.17
in general payments reported to CMS, 2019-2025
11 companies · $1,001 in 2025
The $1,001 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60.00 · 2021: $358 · 2022: $2,253 · 2023: $2,727 · 2024: $674 · 2025: $1,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,997 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,996.83 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,405.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $3,099.61 | 2022-2023 | Xeomin |
| Abbvie INC. | $2,296.73 | 2023-2025 | |
| Allergan, INC. | $1,146.06 | 2021-2022 | |
| Exelixis INC. | $175.00 | 2025 | Cabometyx |
| Janssen Pharmaceuticals, INC | $133.39 | 2023 | Xarelto |
| Astellas Pharma US INC | $87.83 | 2023 | Veozah, Myrbetriq |
| Abiomed | $60.00 | 2019 | |
| Novo Nordisk INC | $26.05 | 2025 | Ozempic, Rybelsus |
| Corcept Therapeutics | $17.29 | 2025 | Korlym |
| Amgen INC. | $17.27 | 2025 | Repatha, Otezla |
| Galderma Laboratories, L.P. | $14.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akhil Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.